These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21148123)

  • 21. Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years.
    Vertosick EA; Häggström C; Sjoberg DD; Hallmans G; Johansson R; Vickers AJ; Stattin P; Lilja H
    J Urol; 2020 Aug; 204(2):281-288. PubMed ID: 32125228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study.
    Aly M; Clements M; Weibull CE; Nordström T; Näslund E; Adolfsson J; Grönberg H
    Eur Urol Focus; 2019 Sep; 5(5):842-848. PubMed ID: 29433987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
    Auvinen A; Rannikko A; Taari K; Kujala P; Mirtti T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Oksala N; Pettersson K; Tammela TL
    Eur J Epidemiol; 2017 Jun; 32(6):521-527. PubMed ID: 28762124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
    Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H
    Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum markers in prostate cancer detection.
    Bratt O; Lilja H
    Curr Opin Urol; 2015 Jan; 25(1):59-64. PubMed ID: 25393274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
    Vickers A; Vertosick EA; Sjoberg DD; Hamdy F; Neal D; Bjartell A; Hugosson J; Donovan JL; Villers A; Zappala S; Lilja H
    J Urol; 2018 Jun; 199(6):1470-1474. PubMed ID: 29366640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening.
    McDonald ML; Parsons JK
    Urol Clin North Am; 2016 Feb; 43(1):39-46. PubMed ID: 26614027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
    Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
    Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
    Heijnsdijk EA; Denham D; de Koning HJ
    Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
    Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
    Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Kallikrein Panel for prostate cancer screening: its economic impact.
    Voigt JD; Zappala SM; Vaughan ED; Wein AJ
    Prostate; 2014 Feb; 74(3):250-9. PubMed ID: 24166488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [PSA and blood test diagnostics of prostate cancer].
    Seikkula H; Pettersson K; Boström PJ
    Duodecim; 2015; 131(17):1547-52. PubMed ID: 26548101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
    Ulmert D; O'Brien MF; Bjartell AS; Lilja H
    Nat Rev Urol; 2009 Jul; 6(7):384-91. PubMed ID: 19578355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(2):601-6. PubMed ID: 25684494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
    Carlsson SV; Peltola MT; Sjoberg D; Schröder FH; Hugosson J; Pettersson K; Scardino PT; Vickers AJ; Lilja H; Roobol MJ
    BJU Int; 2013 Sep; 112(5):602-9. PubMed ID: 23448270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal screening interval for men with low baseline prostate-specific antigen levels (≤1.0 ng/mL) in a prostate cancer screening program.
    Urata S; Kitagawa Y; Matsuyama S; Naito R; Yasuda K; Mizokami A; Namiki M
    World J Urol; 2017 Apr; 35(4):579-586. PubMed ID: 27421271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume.
    Vertosick EA; Zappala S; Punnen S; Hugosson J; Boorjian SA; Haese A; Carroll P; Cooperberg M; Bjartell A; Lilja H; Vickers AJ
    Urology; 2021 Nov; 157():102-106. PubMed ID: 34450175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
    Christensson A; Bruun L; Björk T; Cronin AM; Vickers AJ; Savage CJ; Lilja H
    BJU Int; 2011 Jun; 107(11):1769-74. PubMed ID: 20955263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.